These two Fate series are a great way to pass the time until an official release date drops for the first season of ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

Context Therapeutics (CNTX) announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who ...

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as ...

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research ...

Shares of Context Therapeutics stock opened at $1.21 on Wednesday. The company has a 50 day moving average price of $1.50 and a 200 day moving average price of $1.93. The firm has a market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...